KB 002

Drug Profile

KB 002

Alternative Names: KB002

Latest Information Update: 08 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer KaloBios Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Immunosuppressants; Macrophage inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 07 Aug 2017 KaloBios Pharmaceuticals is now called Humanigen
  • 27 Feb 2013 Efficacy and safety data from a phase I/II trial in Asthma released by KaloBios Pharmaceuticals
  • 28 Oct 2008 BioWa licenses its Potelligent® technology to KaloBios for improvement of antibody-dependent cellular cytotoxicity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top